Trials / Active Not Recruiting
Active Not RecruitingNCT06046729
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 352 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eltrekibart | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2023-10-23
- Primary completion
- 2025-09-30
- Completion
- 2026-08-01
- First posted
- 2023-09-21
- Last updated
- 2025-10-16
Locations
74 sites across 6 countries: United States, Australia, Canada, Germany, Greece, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06046729. Inclusion in this directory is not an endorsement.